EB-1 EA approved TSC non pp

S

SumeetBabu

Registered Users (C)
Thanks to this forum and every one who helped I finally have my EB-1 EA approved. It was a self petition non pp, e-filed, no RFE.
 
SumeetBabu

Congratulations - when did u file EB2-NIW with NSC? My EB2-NIW was filed last October - still waiting. EB1 went to NSC last September - still waiting...
 
Phd
5 years pdf experience
23+ publications (8 1st author, 12 2nd author, others co-author)
40+ abstracts (1 oral presentation)


EVIDENCES
EXHIBIT 1-9
Documents A-Y
Please Note: Evidences are presented as exhibits 1-9, each exhibit consists of documents labeled as A-Y, and some documents are in more than one exhibit, hence exhibit 1-9 are a collection of documents A-Y



INTRODUCTION 5
TO BE CLASSIFIED AS AN INDIVIDUAL WITH EXTRAORDINARY ABILITY (SEC. 203 (B) (1) (A)), I HAVE PROVIDED EVIDENCE FOR THE FOLLOWING: 7

1

Receipt of a lesser nationally or internationally recognized prize for achievement in your field. 7
Exhibit 1 7
Evidence 7
(A) US Patent recite () 7
(B) Support letter from Prof. xxxxxx, Head Department of Cancer Biology and Pharmacology 7
(C) Google patent search 7


2

Membership in associations in your field that require "outstanding achievement" of their members. 8
Exhibit 2 8
Evidence 8
(D) American Association for Cancer Research (AACR) Membership certification 8
(E) AACR active membership criteria 8

3

Material published about you in major trade publications or other major media. 9
Exhibit 3 9
Evidence 9
(F) Impact Factor definition from Wikipedia 9
(G) Publications (published, in press and submitted) 9
(H) Article: cited by Oncogene. 2005 May 26;24(23):3697-707. 9
(I) Article: cited by FEBS JOURNAL 272 (14): 3572-3582 JUL 2005 9
(J) Article: cited by CANCER RESEARCH 65 (3): 1007-1017 FEB 1 2005 9
(K) Article: cited by Anticancer Drugs. 2006 Nov;17(10):1109-17. 9
(L) Article: cited by 2006 Oct;6(10):764-75. Review. 9
(M) Support letter and CV from Dr. xxxxxxxxxxxx (letter was used for approved National Interest Waiver application) 9
(N) Support letter and publication list from Prof. xxxxxx a board member of the Belgian Society for Cell and Development Biology (letter was used for approved National Interest Waiver application) 9
(O) Article: cited by. Clin Cancer Res. 2004 Dec 15;10(24):8250-65. 10
(P) Support letter from xxxxxxxxx, Assistant Professor in Neurophysiology at Bradley University 10

4

Serving as a judge of others in your field either individually or on a panel. 15
Exhibit 4 15
Evidence 15
(Q) E-mail from editor Trends in Biotechnology 15
(R) Article that I received for review 15
(S) ‘Peer Review’ definition from Wikipedia 15
(T) Analysis of Trend in Biotechnology readership and reach 15
(G) Publications (published, in press and submitted, Review paper) 15


5


Original Scientific, scholarly contribution of major significance. 17
Exhibit 5 17
Evidence 17
(A) US Patent recite () 17
(K) Article: cited by. Anticancer Drugs. 2006 Nov;17(10):1109-17. 17
(Q) E-mail from editor Trends in Biotechnology 17
(R) Article that I received for review 17
(S) ‘Peer Review’ definition from Wikipedia 17
(T) Analysis of Trend in Biotechnology readership and reach 17
(G) Publications (published, in press and submitted, Review paper) 17
(N) Support letter and publication list from Prof. xxxxxxxx a board member of the Belgian Society for Cell and Development Biology 17
(B) Prof. xxxxxxx support letter and CV 17
(U) List of citations and Web Of Science search results 17
(V) Reprint requests 17

6

Authorship of scholarly articles in your field. 21
Exhibit 6 21
Evidence 21
(B) Prof. xxxxxxxxx support letter and CV 21
(G) Publications (published, in press and submitted) 21
(K) Article: cited by Anticancer Drugs. 2006 Nov;17(10):1109-17. 21
(L) Article: . cited by Nat Rev Cancer. 2006 Oct;6(10):764-75. Review. 21
(M) Support letter and CV from xxxxxxxx xxxxxxxxxx, Grand Rapids, Michigan 21
(N) Support letter and publication list from Prof. xxxxx, a board member of the Belgian Society for Cell and Development Biology 21
(H) Article: cited by Oncogene. 2005 May 26;24(23):3697-707. 21
(I) Article: cited by FEBS JOURNAL 272 (14): 3572-3582 JUL 2005 21
(J) Article: cited by CANCER RESEARCH 65 (3): 1007-1017 FEB 1 2005 21
(U) List of citations and Web Of Science search results 21
(V) Reprint requests 22

7

Display of your work in exhibitions or showcases. 24
Exhibit 7 24
Evidence 24
(G) Publications (published, in press and submitted) 24
(B) Prof. xxxxxxxx support letter and CV 24
(D) American Association for Cancer Research (AACR) Membership certification 24
(E) AACR active membership criteria 24
(W) AACR annual meeting events and my presentation 24

8

Performing a critical or leading role for organizations that have a distinguished reputation. 27
Exhibit 8 27
Evidence 27
(B) Prof. xxxxxxxxx support letter and CV 27
(G) Publications (published, in press and submitted) 27

9

Commanding a high salary in your field. 30
Exhibit 9 30
Evidence 30
(X) Salary statement and W2s 30
(Y) Association Of American Medical Colleges Report On Medical School Faculty Salaries (2005-2006) 30
CONCLUSIONS 31
OTHER SUPPORTING DOCUMENTS 32
 
Last edited by a moderator:
Sumeetbabu,

Heartfelt congratulations! :) It's no wonder though - you've got a wide spectrum of eligibility criteria covered!

Good luck on your I-485 (whenever you actually get to file it now).
 
Galactus said:
That raises a hmmm. The wonder I believe is more with USCIS and their undue process.. check out post 13 on this thread.
Click to expand...

Well I just got lucky I guess, I see others with better credentials than I getting denied. Probably it is TSC. I listed all that i could. I also noticed an LUD on saturday ???
 
You must log in or register to reply here.
Top